Aussie pharmacies roll up for competing M&A doses

Redirecting to full article in 0 second(s)...

Australia’s pharmacy industry could be next in line for a bout of M&A fever that infected from conglomerate Wesfarmers (WES.AX). The target’s stock, already just above the 21% premium on the table, nudged higher.